retatrutide clinical trials safety efficacy Today, we shared new data from two Phase 3 of retatrutide, our investigational triple agonist. Learn more at our link in bio 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁

The GIP receptor activation in Retatrutide and Tirzepatide appears to provide some gastrointestinal protection compared to pure GLP-1 agonists like Semaglutide

These reductions in A1C levels contribute to better glycemic control and a lower risk of diabetes-related complications

You're getting the same active ingredient with less regulatory oversight

The clinical trial data provides a framework, though individual responses vary

The resulting polypeptides were then eluted and precipitated with salt which provided a new, intermediate starting material that was then separated with chromatography (Jrnvall, Agerberth, Zasloff)

This product is not intended to diagnose, treat, cure, or prevent any disease.